About Us

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors.

Aleta Bio has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity.

Co-founders Paul Rennert and Roy Lobb bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise.

Leadership Team

Aleta is led by a team with significant biotechnology entrepreneurial and CAR-T drug development experience and supported by the field’s leading scientific and clinical advisors.

paul-rennert

Paul Rennert

President & CSO – Aleta

  • PI, Biogen: Inflammation, autoimmunity, fibrosis, oncology
  • Since 2012 focused on new company development
  • Author on more than 30 patents and approx. 100 publications & recent IO reviews

View Bio

roy-lobb

Roy Lobb

Director – Aleta

  • Founder/co-founder of 7 biotechs including Avila Therapeutics ($355M Celgene acquisition)
  • Advent Life Sciences venture partner
  • Former head of Biogen R&D, asst. professor pathology at HMS, PhD Univ. Oxford (Chemistry)

View Bio

MarkL_440_CP

Mark Leuchtenberger

Executive Chairman – Established life sciences executive with leadership roles at multiple companies in the life sciences space

  • Formerly CEO of Brooklyn ImmunoTherapeutics and Chairman.
  • Previous CEO and Board roles at multiple biopharma companies, achieving product launches and M&A exits
  • Led the development and launch of Biogen flagship product Avonex in US and internationally

View Bio

raj-parekh

Raj Parekh

Director

  • General Partner – Advent
  • Founder & board leadership roles at Glycosciences, Galapagos, Celldex,
  • Trained at Oxford

View Bio

Damia-Tormo-picture

Damia Tormo

Director

  • Managing Partner and co-founder of Columbus Venture Partners
  • Previous CEO of Highlight Therapeutics and Artax Biopharma
  • Founder of Highlight Therapeutics, Artax Biopharma, Viralgen, Vivet Therapeutics, Polypeptide Therapeutic Solutions, Tyris Therapeutics, and Radioterapia de Protones

View Bio

Eva-Lotta-Allan_bio-picture

Eva-Lotta Allan

Non-Executive Director

  • Chairman of C4X Discovery and Draupnir Bio, Non-Executive Director of Almirall, Targovax and Crescendo Biologics (current)
  • Previous Chief Business Officer at Immunocore and Chief Business Officer and member of the Executive Committee and Euronext IPO team at Ablynx NV
  • Held senior positions at various large-cap biotechnology companies including Vertex Pharmaceuticals

View Bio

Find Out More

View our Scientific Advisory Board

Find out more about Aleta BioTherapeutics and the people who bring our extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise.